PHAT$5.742.96%-0.175
Pre-market: 5.80+0.06 +1.05%
Phathom Pharmaceuticals Inc (PHAT)
Date: 2026-11-03 16:00O: 5.92H: 6.11L: 5.50C: 5.74Vol: 2.163M
Phathom Pharmaceuticals Inc stock is traded at $5.74, with a volume of 2,162,820. It is down -2.96% in the last 24 hours and down -17.05% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Previous Close:
$5.92
Open:
$5.92
24h Volume:
2,162,820
Relative Volume:
0.93
Market Cap:
$466.61M
Revenue:
$204.89M
Net Income/Loss:
-$157.30M
P/E Ratio:
-
EPS:
-$2.11
Net Cash Flow:
-$97.76M
1W Performance:
-8.60%
1M Performance:
-17.05%
6M Performance:
-55.40%
1Y Performance:
-57.45%
1-Day Range:
$0.00$0.00
1-Week Range:
$5.50$7.00
52-Week Range:
$5.02$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
(877) 742-8466Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading
- Parikh AsitMay 20 '26Director
- Transaction
- Option Exercise
- Cost
- $4.95
- #Shares
- 17,500
- Value ($)
- 86,625
- #Shares Total
- 52,122
- Parikh AsitJan 13 '26Director
- Transaction
- Option Exercise
- Cost
- $10.30
- #Shares
- 8,750
- Value ($)
- 90,125
- #Shares Total
- 131,000
- Parikh AsitDec 19 '25Director
- Transaction
- Option Exercise
- Cost
- $10.30
- #Shares
- 8,750
- Value ($)
- 90,125
- #Shares Total
- 122,250
- Basta Steven LNov 28 '25President and CEO
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 90,000
- Value ($)
- 0
- #Shares Total
- 131,625
- Breedlove Robert CharlesNov 03 '25Principal Accounting Officer
- Transaction
- Sale
- Cost
- $13.51
- #Shares
- 524
- Value ($)
- 7,079
- #Shares Total
- 47,407
- President and CEO
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 90,000
- Value ($)
- 0
- #Shares Total
- 90,000
